Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.

ABSTRACT: Recently, we observed that telomeres of BRCA1/2 mutation carriers were shorter than those of controls or sporadic breast cancer patients, suggesting that mutations in these genes might be responsible for this event. Given the contradictory results reported in the literature, we tested whether other parameters, such as chemotherapy, could be modifying telomere length (TL). We performed a cross-sectional study measuring leukocyte TL of 266 sporadic breasts cancer patients treated with first-line chemotherapy, with a median follow-up of 240 days. Additionally, we performed both cross-sectional and longitudinal studies in a series of 236 familial breast cancer patients that included affected and non-affected BRCA1/2 mutation carriers. We have measured in leukocytes from peripheral blood: the T

SUBMITTER: Benitez-Buelga C 

PROVIDER: S-EPMC4824277 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature